Analyst cuts Allergan generics sales estimates as Teva deal close nears

Teva

Teva is jumping through hoops to close its $40 billion-plus deal for Allergan’s generics unit--but when it does, it may not be raking in as much as analysts initially thought.

Deutsche Bank Thursday lowered its sales estimates for the unit--dubbed Actavis Generics--by about 8% to reflect Q1 sales that came in about 20% below where they were last year.

Teva’s investors shouldn’t panic, though. The Israeli drugmaker has said it expected that sales drop, considering the strength of last year’s Q1. And DB’s Gregg Gilbert pointed out some bright spots for the generics giant, too: It trimmed SG&A estimates for Actavis Generics, and it raised its U.S. sales estimates for Teva’s branded blockbuster Copaxone, too.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

Teva has been working hard to usher the Allergan deal--struck last summer--through the door, but a close look from antitrust regulators has been holding things up. Bernstein analyst Ronny Gal, though, has said the acquisition still looks as though it’s on track to close this month, and the pharma has already struck a pair of deals within the past week to clear FTC hurdles: Thursday, Schaumburg, IL’s Sagent Pharmaceuticals agreed to shell out $40 million for a portfolio of 5 generics not yet FDA-approved, and Saturday, Dr. Reddy’s inked a $350 million pact to acquire 8 meds from the Petah Tivka-based company.

Pharma deals lately have come under the antitrust lens more often than mergers in other industries, according to a Bloomberg analysis released last week. The FTC reviewed drugmakers’ tie-ups at about three times the rate of other transactions--in part because the recent trend toward skyrocketing drug prices.

- read Sagent's release 

Special Reports: Top 20 generics companies by 2014 revenue - Teva - Allergan

Related Articles:
Pharma deals get extra FTC scrutiny--but it hasn't stopped rising drug costs: Bloomberg​
Teva, Allergan generics deal on track to close in June: Analyst
Teva hits roadblock in Allergan buy, hindering 'Pfizergan'
Teva speeds toward Allergan deal close with EU thumbs up
Teva's Copaxone finally succumbs to copycats, putting a drag on 2015 sales
Forget Mylan: Teva inks $40B-plus pact for Allergan's generics biz

Suggested Articles

Acadia's knew it had a winner in psychosis when it called off a trial for its Nuplazid. Now analysts are seeing a blockbuster in the making.

Sandoz would still consider acquisitions, as long as they fit the Novartis unit's focus on generics and biosimilars, CEO Richard Saynor said.

Novartis is planning 80 major drug submissions in key markets over the next three years, and 25 of those could be blockbuster opportunities.